Teladoc Health, Inc. 8-K

What Happened
Teladoc Health, Inc. filed an 8-K reporting the final voting results from its Annual Meeting of Stockholders held May 21, 2026. All director nominees were elected to serve until the 2027 annual meeting. Stockholders also approved the advisory vote on executive compensation (say-on-pay) and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Directors elected (terms to 2027): Charles Divita, III; Sandra L. Fenwick; Catherine A. Jacobson; Kenneth H. Paulus; Susan R. Salka; David L. Shedlarz; Mark Douglas Smith, M.D., MBA; Michael S. Smith; David B. Snow, Jr. (example vote: David B. Snow, Jr. — For: 67,368,308; Against: 12,899,237; Abstentions: 1,018,096).
• Advisory vote on named executive officer compensation: For 71,154,268; Against 8,973,257; Abstentions 1,158,116; Broker non-votes 43,207,208.
• Auditor ratification: Ernst & Young LLP ratified — For 122,580,992; Against 1,195,800; Abstentions 716,057 (broker non-votes N/A for this ratification).
• Broker non-votes of 43,207,208 were recorded on the director elections and the say-on-pay vote.

Why It Matters
These results confirm board continuity and governance outcomes investors watch: directors were reappointed, the board’s executive compensation approach received majority advisory support, and the company retained its independent auditor for 2026. The sizable broker non-vote total (43.2M) is notable because those shares did not participate in several contested votes, which can affect margins on governance items. This filing is primarily governance-related (director elections, say-on-pay, auditor ratification) rather than reporting financial results.